女士冠脉介入治疗效果不如男士!JACC汇总分析21项随机研究

2020-04-11 朱朱 中国循环杂志

近期,JACC发表一项包含21项冠脉介入治疗(PCI)随机研究的汇总分析表明,PCI术后5年时,女士中主要不良心血管事件(心原性死亡、心肌梗死、缺血驱动的靶病变血运重建)和缺血驱动的靶病变血运重建发生

近期,JACC发表一项包含21项冠脉介入治疗(PCI)随机研究的汇总分析表明,PCI术后5年时,女士中主要不良心血管事件(心原性死亡、心肌梗死、缺血驱动的靶病变血运重建)和缺血驱动的靶病变血运重建发生风险均高于男士。

这21项研究共纳入32 877例冠心病患者,其中女士占27.8%。

与男士相比,女士年龄较大,体重指数较高,高血压和糖尿病合并比例较高,而既往接受血运重建的比例较低。

冠脉造影数据显示,女士的冠脉病变参考血管直径较小,病变较短。

PCI术后5年时,女士中主要不良心血管事件(18.9% vs. 17.7%)、全因死亡(10.4% vs. 8.7%)、心原性死亡(4.9% vs. 4.0%)、缺血驱动的靶病变血运重建(10.9% vs. 10.2%)发生率均明显高于男士。

多因素分析表明,女性是主要不良心血管事件和缺血驱动的靶病变血运重建的独立预测因素。

PCI术后女士出现主要不良心血管事件和缺血驱动的靶病变血运重建的风险较男士分别增加14%和23%,但全因死亡和心原性死亡风险相似。

来源:Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention. J Am Coll Cardiol, 2020, 75(14): 1631-1640.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-05-16 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-04-11 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-04-11 肿瘤克星

    高质量研究,读起来真爽,谢谢梅斯

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2053576, encodeId=26fa20535e658, content=<a href='/topic/show?id=5e5b6429291' target=_blank style='color:#2F92EE;'>#汇总分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64292, encryptionId=5e5b6429291, topicName=汇总分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3516494, createdName=spoonycyy, createdTime=Sat Sep 19 15:24:30 CST 2020, time=2020-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1894151, encodeId=cc7e189415172, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Mon Apr 20 06:24:30 CST 2020, time=2020-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854733, encodeId=a1e31854e3367, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Sat May 16 16:24:30 CST 2020, time=2020-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941979, encodeId=c9c019419e9a5, content=<a href='/topic/show?id=338b98462fa' target=_blank style='color:#2F92EE;'>#随机研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98462, encryptionId=338b98462fa, topicName=随机研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=jiangjun073, createdTime=Thu Jan 07 08:24:30 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326577, encodeId=2dd413265e712, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443547, encodeId=6841144354e79, content=<a href='/topic/show?id=1ed0309444e' target=_blank style='color:#2F92EE;'>#冠脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30944, encryptionId=1ed0309444e, topicName=冠脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/8u3mGRpJpSHpz8GnN2RDHUVc5Vm6yUoQhqesfhJoyZjndetgiaQV6z9uzia2U2DkZ8ZWXqJBZTHXxib22b7nngyhw/132, createdBy=f44f5082140, createdName=12498ebem20暂无昵称, createdTime=Mon Apr 13 02:24:30 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032474, encodeId=d5fe10324e493, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038918, encodeId=7fe110389182a, content=高质量研究,读起来真爽,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047034, encodeId=a216104e0341a, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Sat Apr 11 14:24:30 CST 2020, time=2020-04-11, status=1, ipAttribution=)]
    2020-04-11 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

相关资讯

肥胖女性练普拉提身心受益!美国高血压杂志研究

肥胖不是好事!不仅形象不好,而且预示高血压和早期血管并发症的风险。

Circulation:既往十年,女性在心血管试验中的参与情况

心血管疾病是世界范围内女性的首要死因,但女性在心血管试验中的代表性历来不足。本研究系统的评估了2010年-2017年期间已完成的心血管试验中女性的参与情况,并记录了包括疾病类型、资助类型、国家、试验规模、干预类型和试验参与者的人口统计特征。研究人员计算了每个试验的男女比例,并通过将女性在试验参与者中的百分比除以女性在疾病人口中的百分比,明确女性参与的预估值(参与比率在0.8-1.2表明患病率相当和

Arthritis Rheumatol:女性哮喘、慢阻肺与随后出现类风湿性关节炎的风险

哮喘和COPD均与偶发性RA的风险升高相关,而与吸烟状况/强度和其他潜在混杂因素无关。

Ann Intern Med:70岁以上女性持续年度乳腺钼靶筛查与乳腺癌死亡率

由此可见,与停止筛查相比,持续年度乳腺癌筛查并未大幅降低75岁以上的女性8年乳腺癌死亡率。

JAMA:女性绝经后动脉硬化明显加速!

浙江大学医学院附属第一医院、湘雅第三医院和英国伦敦国王学院等学者在JACC上刊登研究称,男性和女性在血管老化和动脉硬化机制存在差异。

屠呦呦入选《时代周刊》100位更具影响力女性人物榜

澎湃新闻记者注意到,@盖茨基金会 官方微博在今年3月8日妇女节发布消息:中国科学家屠呦呦近日入选《时代周刊》100位最具影响力女性人物榜。